Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
80 Leser
Artikel bewerten:
(0)

Research and Markets - Global Viscosupplementation Market 2016-2020 with Sanofi, Anika Therapeutics, Seikagaku, Fidia Farmaceutici & Ferring Pharmaceuticals Dominating

DUBLIN, Dec 9, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Viscosupplementation Market 2016-2020" report to their offering.

The global viscosupplementation market to grow at a CAGR of 6.23% during the period 2016-2020.

Global Viscosupplementation Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The shift in consumer preference from cheaper five-injection cycle products to premium priced single-injection cycle products is a major positive trend being witnessed in the market in recent years. Despite its exorbitant cost, consumers are increasingly going for single-injection cycle viscosupplements because of shorter treatment time.

According to the report, fast-growing geriatric population is the major driver driving growth in the market. A rising concern worldwide is the fast-growing elderly population, especially in the major countries such as Japan, South Korea, China, Germany, and the US. The geriatric people in these countries are affected by a wide range of chronic diseases such as cancer, liver, osteoarthritis, and kidney diseases.

Further, the report states that the increase in the number of substitutes for viscosupplementation is the major challenge being faced by the manufacturers in the market. NSAIDs, knee replacement devices, cyclooxygenase inhibitors, and joint arthroplasty devices are the substitutes for viscosupplements used in the treatment of knee osteoarthritis.

Key vendors

  • Sanofi
  • Anika Therapeutics
  • Seikagaku
  • Fidia Farmaceutici
  • Ferring Pharmaceuticals

Other prominent vendors

  • Allergan
  • Contipro Biotech
  • DePuy Synthes
  • F. Hoffmann-La Roche
  • Galderma
  • HTL Biotechnology
  • Hyaltech
  • Expanscience Laboratoires
  • Lifecore Biomedical
  • Lipo Chemicals
  • Merz Aesthetics
  • Mylan
  • Nordic Drugs
  • Shandong Freda Biochem
  • Shanghai Jingfeng Pharmaceutical
  • Smith & Nephew
  • TEIJIN PHARMA
  • TRB Chemedica International

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Market segmentation by products

Part 07: Geographical segmentation

Part 08: Market drivers

Part 09: Impact of drivers

Part 10: Market challenges

Part 11: Impact of drivers and challenges

Part 12: Market trends

Part 13: Vendor landscape

Part 14: Key vendor analysis

Part 15: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/drlxnm/global

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.